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Key Clinical Message
The cost of treating metastatic colorectal cancer has increased significantly after
the introduction of targeted antivascular therapies. We report the unusual case
of a patient with colorectal cancer with several large liver metastases at diagno-
sis, who was cured after removal of the primary tumor and treatment with 5-
FU/LV only.
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Introduction
Colorectal cancer (CRC) is the second most common
cause of cancer-related mortality in both men and women
and the third most common type of cancer in the United
States. Until 2000, 5-fluorouracil/leucovorin (5-FU/LV)
had been the standard of therapy for metastatic colorectal
cancer (mCRC). Response rates (RR) of 21% and overall
survivals (OS) of 11.7 months have been reported with 5-
FU/LV compared to 11% and 11 months, respectively,
with 5-FU alone [1]. Long-term survival in patients with
mCRC receiving palliative 5-FU/LV chemotherapy only
has been described but it occurs rarely [2–4]. We report
an unusual case of a patient with recto-sigmoid cancer
with several large liver metastases at diagnosis who under-
went surgery of the primary tumor, received chemother-
apy with 5-FU/LV for 1 year, and currently is alive with
disease-free survival of more than 12 years.
Case Report
A 72-year-old woman with past medical history of hyper-
tension and bronchial asthma presented to the emergency
department in August 2000 complaining of intermittent
rectal bleeding accompanied by 6 months of colicky
abdominal pain. Family history was unremarkable for
cancer and the patient had never used tobacco or alcohol.
She had stable vital signs and a normal physical examina-
tion on admission. An abdomino-pelvic CT scan revealed
irregular thickening of the sigmoid colon, suggesting a
nonobstructing sigmoid mass. Three hypodense liver
lesions, measuring 8 9 5 cm, 6 9 5 cm, and 2 cm,
respectively, also were noted (Figs. 1).
She subsequently underwent colonoscopy with a biopsy
of the apple-core lesion at the recto-sigmoid junction,
which came back positive for an adenocarcinoma. Then,
she underwent recto-sigmoid resection and liver inspec-
tion during the surgical intervention. Two large liver
masses were palpated. Examination of the surgical speci-
men revealed moderately differentiated adenocarcinoma
with subserosal invasion and negative surgical margins.
Metastatic adenocarcinoma was removed from the peri-
colic fat (8 9 4 9 2.5 cm mass). The tumor was staged
as T3N1M1. Carcinoembryonic antigen (CEA) levels were
9.14 ng/mL before surgery. Palliative chemotherapy was
initiated within 4 weeks following resection, with the Ros-
well Park regimen [5] consisting in weekly 5-FU
(500 mg/m2) and LV (20 mg/m2) for 6 weeks followed by
a 2-week drug-free period for 1 year. She received the last
dose of chemotherapy in September 2001. Of note,
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1 month following the initial diagnosis of colon cancer,
the patient was readmitted to the hospital in September
2000 for an acute saddle pulmonary embolism. Anticoag-
ulation with Coumadin was initiated and the patient was
maintained on Coumadin until the present time.
A CT scan of the abdomen 3 months after comple-
tion of 1 year of chemotherapy revealed complete reso-
lution of liver metastases. CEA levels decreased as well,
from 9.14 ng/mL at diagnosis to 0.5 ng/mL 2 months
after surgery. No mucosal recurrence was seen on fol-
low-up colonoscopies in August 2005 and January
2009. Yearly follow-up CT scans of the abdomen and
pelvis were grossly normal (Fig 2). The last CT scan of
the abdomen and pelvis, done in September 2013, did
not reveal any signs of metastatic disease. She has been
in complete remission since 2001, off all treatment,
with no evidence of tumor recurrence as of 6 Septem-
ber 2013. A complete sequencing of her genome done
at Ludwig Center for Cancer Research did not reveal
any salient features that may explain her long survival
(Dr. Bert Vogelstein, pers. commun.).
Discussion
Survival of patients with mCRC has advanced steadily
over the past decade. A retrospective review done on
2470 patients followed at two large cancer centers, MD
Anderson and Mayo Clinic, found that the OS rate
increased from 9.1% for patients diagnosed in 1990–1997
to 13% for those diagnosed in 1998–2001, 19.2% for
those diagnosed in 2001–2003, and an estimated 5-year
survival rate of 32% for patients diagnosed in 2004–2006
[6]. These improvements were likely due to both an
increase in the number of hepatic metastetectomies and
more efficacious chemotherapy regimens.
In 2000, Saltz published the results of a randomized
Phase III study that compared Irinotecan and bolus 5-
FU/LV with the Mayo Clinic regimen of 5-FU/LV. In this
study, the Irinotecan combination demonstrated a near
doubling of response rate (51% vs. 28%) [7]. Almost at
the same time, in a European trial, de Gramont showed
that an Oxaliplatin/infusional 5-FU/LV regimen (FOL-
FOX4) compared with 5-FU/LV alone produced a 51%
versus 22% response rate, also with a statistically signifi-
cant improvement in progression-free survival
(9.0 months vs. 6.2 months) [8]. The median OS for
patients with metastatic colon cancer treated with a 5-
fluorouracil (5-FU)-based regimen improved from
approximately 12 months to an OS of more than
18 months with the FOLFOX regimen [9]; primarily, it
has been the newer combinations of chemotherapy and
biological agents such as Bevacizumab, Cetuximab, and
Panitumumab that led to a substantial jump in OS, which
went beyond 2 years in some studies [10].
As per current NCCN guidelines (v.3.2014), combina-
tion therapy with FOLFOX, FOLFIRI, CapeOX, FOLFOX-
IRI and Bevacizumab, Cetuximab, or Panitumumab as
well as 5-FU/LV or Capecitabine alone or in combination
with Bevacizumab are recommended regimens for the
first-line treatment of mCRC.
In rare cases, mCRC patients may have prolonged sur-
vival with 5-FU-based regimens. There have been three
Figure 2. Postcontrast CT image through the upper abdomen
acquired 10 years after the initial presentation demonstrates no
residual or recurrent masses within the liver.
Figure 1. Postcontrast CT image through the upper abdomen at
initial presentation showing two large hypo-attenuating masses in the
right and left hepatic lobes, respectively, (single arrows). Note the
perihepatic ascites (double arrows).
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case series published so far that showed long-term sur-
vival (LTS) of mCRC treated with systemic chemotherapy
alone (Table 1).
The North Central Cancer Treatment Group and Mayo
Clinic reported long-term survival beyond 5 years from
initiation of chemotherapy for mCRC [2]. This study
included patients treated from 1972 to 1995. Thirteen
patients out of 3407 treated with chemotherapy (0.4%)
had no evident site of disease involvement for >5 years
from last treatment. The longest survival achieved in this
series was 23 years after completing the chemotherapy.
Twelve out of the thirteen patients who achieved LTS
were treated with 5-FU-based regimens. The second study
was a retrospective review of 2751 patients who presented
with mCRC at MD Anderson from 1990 to 2003. [3]. In
the final analysis, 2541 patients were included, of which
six (0.24%) were without evidence of disease after an
average follow-up of 10.3 years. In this series, the longest
survival achieved was 15.1 years after diagnosis. The use
of 5 FU-based regimens also was associated with LTS in
this series, as five of the six patients who achieved LTS
were treated with 5-FU-based regimens. A third study,
published in the French literature, included 445 mCRC
patients; three patients treated with 5-FU-based chemo-
therapy (of whom one was lost from follow-up after
6.3 years) achieved complete remission [4]. In this series,
the longest survival achieved was 14 years. However, one
of the limitations of studies and case reports on LTS is
that the inherent tumor biology is unknown; thus, the
contribution of this variable to treatment-associated LTS
cannot be established and remains a potential confound-
ing factor [2]. In general, it is difficult to distinguish
between cases where response to treatment (i.e., complete
remission) prolongs survival and cases where the favor-
able prognosis is due to intrinsic patient factors differing
from response [11]. Individual patients may have both
tumors that are uniquely sensitive to chemotherapy and
genetic or epigenetic characteristics that confer them a
survival advantage.
5-FU/LV still may be an effective treatment for a small
subgroup of patients with tumors sensitive to this drug
combination. 5-FU is a fluoropyrimidine that inhibits thy-
midylate synthase, which leads to inhibition of DNA syn-
thesis and DNA repair [12]. Leucovorin (LV) is added to
it in order to enhance its effect on cancer metabolism. Sig-
nificant attempts have been made in order to identify bio-
markers associated with 5-FU/LV response, with particular
attention given to the enzymes involved in the metabolism
of 5-FU. The results evaluating the levels of thymidylate
synthase, thymidine phosphorylase, and dihydropyrimi-
dine dehydrogenase have been inconclusive (reviewed in
[13]). In 2003, using a gene expression profiling approach,
John et al. described a panel of 50 genes significantly asso-
ciated with 5-FU response [13]. More recent clinical data
suggest an association between 5-FU response and replica-
tion error status. In an in vitro study using a large panel
of CRC cell lines, 5-FU response was associated signifi-
cantly with mismatch repair deficiency [14]. Also, a recent
meta-analysis that reviewed data from 2,402 patients
receiving 5-FU treatment for CRC found that the thymi-
dylate synthetase genotype of the lowest protein expres-
sion (2R/2R) was associated significantly with improved
clinical benefit (the pooled risk ratio was relative
risk = 1.36 [1.11, 1.65]; P = 0.003); however, this effect
size was too small to be considered clinically useful [15].
In our patient, the complete sequencing of her genome
was noncontributory, but it is possible that her long sur-
vival may have been related to still unidentified specific
genetic or epigenetic factors.
The resection of the primary tumor may have also
had an impact on the LTS of our patient. Five of the
six patients in the MD Anderson series underwent resec-
tion of their primary tumor and all three patients from
the French series had their primary tumor resected. The
status of the primary tumor was not reported in the ser-
ies from North Central Cancer Treatment Group and
Mayo Clinic. A multivariate analysis of 1155 individual
patients’ data from four randomized trials presented in
2012 at ASCO confirmed that primary tumor resection
in patients with CRC and unresectable metastasis was an
independent predictor of better OS (HR: 0.63 [0.53–
0.75]; P < 0.0001) and may be a surrogate for progres-
sion-free survival (PFS) (HR: 0.82 [0.70–0.95];
P = 0.0007) [16].
Did Coumadin anticoagulation given in combination
with the 5FU/LV chemotherapy plays a role in this
patient’s long-term survival? Thirty years ago, a study on
the clinical and pharmacokinetic effects of combined War-
farin and 5-FU in advanced colon cancer showed a greater
overall median survival for patients who received the com-
bined therapy of Warfarin and 5-FU (19.2 months), but
these earlier results were never reproduced [17]. Warfarin
is extensively metabolized by several cytochrome P450
enzymes. 5FU is not a substrate for hepatic drug metabo-
Table 1. mCRC long-term survival case series.
No. of patients
treated only
with
chemotherapy
with LTS
Treatment
duration
(months)
No
evidence
of disease
(years)
after CR
Percentage
of patients
achieving
LTS Reference
13 21
(average)
7.6–23 0.34% [2]
3 8–12 6.3–13.5 0.67% [3]
6 10–54 6.9–14.4 0.24% [4]
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lizing CYP enzymes but an interaction between 5FU and
the CYP enzymes has been previously described [18, 19].
No toxicity related to the concomitant use of 5FU and
Warfarin was observed in our patient.
Conclusion
The cost of treating mCRC has increased dramati-
cally after the introduction of targeted antivascular
therapies.
Colorectal cancer is a heterogeneous disease with a
wide variety of biologic abnormalities, making each
patient and each tumor unique. 5-FU/LV still may be
an effective treatment for a small subgroup of patients
with tumors that are sensitive to this drug combina-
tion. The development of more refined molecular biol-
ogy techniques may allow oncology practitioners to
predict which patients may benefit from this combina-
tion. Our case demonstrates the possibility of curing
mCRC using 5-FU/LV, even in patients bearing a high
tumor burden.
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